Cochlear Neurotrophin-3 overexpression at mid-life prevents age-related inner hair cell synaptopathy and slows age-related hearing loss

Luis R. Cassinotti1 | Lingchao Ji1 | Beatriz C. Borges1 | Nathan D. Cass1 | Aditi S. Desai1 | David C. Kohrman1 | M. Charles Liberman2 | Gabriel Corfas1

1Kresge Hearing Research Institute and Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA
2Eaton-Peabody Laboratories, Massachusetts Eye & Ear, and Department of Otolaryngology, Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA

Abstract

Age-related hearing loss (ARHL) is the most prevalent sensory deficit in the elderly. This progressive pathology often has psychological and medical comorbidities, including social isolation, depression, and cognitive decline. Despite ARHL's enormous societal and economic impact, no therapies to prevent or slow its progression exist. Loss of synapses between inner hair cells (IHCs) and spiral ganglion neurons (SGNs), a.k.a. IHC synaptopathy, is an early event in cochlear aging, preceding neuronal and hair cell loss. To determine if age-related IHC synaptopathy can be prevented, and if this impacts the time-course of ARHL, we tested the effects of cochlear overexpression of neurotrophin-3 (Ntf3) starting at middle age. We chose Ntf3 because this neurotrophin regulates the formation of IHC-SGN synapses in the neonatal period. We now show that triggering Ntf3 overexpression by IHC supporting cells starting in middle age rapidly increases the amplitude of sound-evoked neural potentials compared with age-matched controls, indicating that Ntf3 produces a positive effect on cochlear function when the pathology is minimal. Furthermore, near the end of their lifespan, Ntf3-overexpressing mice have milder ARHL, with larger sound-evoked potentials along the ascending auditory pathway and reduced IHC synaptopathy compared with age-matched controls. Our results also provide evidence that an age-related decrease in cochlear Ntf3 expression contributes to ARHL and that Ntf3 supplementation could serve as a therapeutic for this prevalent disorder. Furthermore, these findings suggest that factors that regulate synaptogenesis during development could prevent age-related synaptopathy in the brain, a process involved in several central nervous system degenerative disorders.

KEYWORDS

age-related hearing loss, auditory nerve, hidden hearing loss, neurotrophins, synapse regeneration

Abbreviations: AAV, adeno-associated virus; ABR, auditory brainstem response; ARHL, age-related hearing loss; CMV, cytomegalovirus; dB, decibel; DPOAE, distortion products otoacoustic emissions; HCs, hair cells; IHC, inner hair cell; Ntf3, neurotrophin-3; OHC, outer hair cell; SGN, spiral ganglion neuron; SPL, sound pressure level; Tmx, tamoxifen.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.
Age-related hearing loss (ARHL), also known as presbycusis, is the most prevalent sensory deficit in the elderly, affecting a third of people over age 65 and half of those over 85 in the US (Agrawal et al., 2008; Bainbridge & Wallhagen, 2014). This disorder is characterized by increasing progressive elevation of hearing thresholds and increasing difficulties with speech comprehension, especially in noisy environments. ARHL is also often associated with psychological and medical comorbidities, including social isolation, frailty, depression, and cognitive decline (Livingston et al., 2020; Powell et al., 2021). Despite its enormous societal and economic impact (Hudgill et al., 2017), no therapies to prevent or slow ARHL exist.

While the cellular and molecular mechanisms of ARHL remain poorly understood, studies in mice and humans indicate that loss of synapses between inner hair cells (IHCs) and spiral ganglion neurons (SGNs), a.k.a. cochlear or IHC synaptopathy, is an early pathology that precedes IHC loss in mice (Sergeyenko et al., 2013) and humans (Makary et al., 2013; Viana et al., 2015; Wu et al., 2019). Furthermore, studies in mice showed that noise-induced IHC synaptopathy at an early age accelerates the onset of SGN loss and age-related threshold increases (Kujawa & Liberman, 2006). Based on these observations, we wondered if age-related IHC synaptopathy can be prevented or delayed, and if achieving that alters the progression of ARHL. For this, we focused on neurotrophin-3 (Ntf3), a neurotrophic factor critical for the survival of SGNs during embryogenesis (Ernfors et al., 1995; Farinas et al., 1994) which we showed regulates the formation of IHC-SGN synapses in the neonatal period and induces their regeneration and functional recovery after acoustic injury in young mice (Wan et al., 2014). Moreover, using a reporter mouse in which β-galactosidase is co-expressed with Ntf3 (Farinas et al., 1994), we showed that cochlear Ntf3 expression decreases during aging (Sugawara et al., 2007), suggesting that lower Ntf3 levels could contribute to ARHL.

Here, we tested the impact of persistent Ntf3 overexpression starting at middle age on ARHL using transgenic mice. We show that induction of IHC supporting cell Ntf3 overexpression in 1-year-old mice rapidly (within 1 week) increases the amplitude of sound-evoked cochlear potentials, something that does not occur in young mice, indicating that Ntf3 treatment acutely enhances aspects of cochlear function in middle-aged mice with mild hearing impairment. Furthermore, Ntf3 overexpression slows the progression of ARHL, that is, as they approach the end of their lifespan (95 weeks of age), Ntf3 overexpressing mice have less age-related IHC synaptopathy and stronger sound-evoked potentials along the ascending auditory pathway than their age-matched controls. Together, these results support the notion that age-related decrease in cochlear Ntf3 expression contributes to ARHL and that Ntf3 supplementation could serve as a therapeutic for this prevalent disorder.

To determine the impact of increasing supporting cell Ntf3 expression on the time-course of ARHL, we studied two cohorts of mice. One group (Ntf3Stop:Slc1a3/CreER<sup>T</sup>) carried an inducible Ntf3 transgene (Ntf3<sup>Stop</sup>) (Wan et al., 2014) and the CreER<sup>T</sup> recombinase transgene under the control of the GLAST (Slc1a3) promoter (Wang et al., 2012) to drive Ntf3 overexpression in inner border and inner phalangeal cells, the supporting cells immediately surrounding the IHCs and their synaptic connections with auditory nerve fibers. We chose this approach, because we previously showed that Ntf3 overexpression in these supporting cells promotes formation of supernumerary IHC-SGN synapses in the neonatal period and induces synapse regeneration and functional recovery after acoustic injury in young mice (Wan et al., 2014). The control group consisted of littermates carrying only the Ntf3<sup>Stop</sup> transgene, and therefore, have normal levels of Ntf3 expression even after tamoxifen treatment (Wan et al., 2014). At 59 weeks of age, we measured baseline auditory function in both cohorts by recording distortion product otoacoustic emissions (DPOAEs) and auditory brainstem responses (ABRs) (Figure 1a). DPOAEs reflect outer hair cell (OHC) function; ABRs reflect the function of the ascending auditory system, from the activation of IHCs and SGNs to the inferior colliculus (Kohman et al., 2021).

The groups exhibited no differences in DPOAE and ABR thresholds at the baseline time point (59 weeks, Figure 1b,c). Furthermore, at this time point, the groups did not differ in the amplitudes of the first peak of the ABR waveform (Figures 1d and 2a), which reflects the synchronous activity of SGNs in response to sound. Analysis of the later peaks in the ABR waveforms (Figure 2b) indicated that signaling along the ascending auditory pathway at baseline was similar between the groups as well.

All animals were treated with tamoxifen at 60 weeks of age to induce CreER<sup>T</sup>-mediated activation of the Ntf3<sup>Stop</sup> transgene, which occurs only in mice carrying the Slc1a3/CreER<sup>T</sup> allele, and auditory function was followed longitudinally in both cohorts. Notably, 1 week after activation of Ntf3 overexpression (61 weeks of age), the suprathreshold ABR peak 1 amplitudes in Ntf3<sup>Stop</sup>:Slc1a3/CreER<sup>T</sup> mice were higher than in age-matched controls (Figures 1d, 2a and 3a), indicating that increased Ntf3 availability leads to an acute increase in the sound-evoked potentials mediated by IHC-SGN synapses. Interestingly, activation of the Ntf3 transgene did not alter ABRs and DPOAE thresholds or ABR1 peak 1 amplitudes in young (8-week-old) mice (Figure 3b). Since by 59 weeks, the mice already exhibit a mild but significant reduction in ABR peak 1 amplitudes (Figure S1), and cochlear Ntf3 expression steadily decreases with age (Sugawara et al., 2007), these data suggest that Ntf3 overexpression can have acute effects on ABR peak 1 amplitudes only when Ntf3 endogenous levels are reduced.

As the animals aged, both groups showed similar increases in DPOAE and ABR thresholds (Figure 1b,c), indicative of ARHL. However, suprathreshold ABR peak 1 amplitudes were higher in Ntf3<sup>Stop</sup>:Slc1a3/CreER<sup>T</sup> than in the age-matched Ntf3<sup>Stop</sup> controls at all post-tamoxifen
time points (Figure 1d) and all test frequencies (Figure 2a), indicating that Ntf3 overexpression preserves the number and/or strength of connections between IHCs and SGNs during aging, all along the cochlear axis. Importantly, Ntf3 overexpression also enhanced most of the later peaks in the ABR waveforms at 95 weeks of age (Figure 2b and Figure S2), showing that the Ntf3-mediated increase in ABR peak 1 amplitudes is also reflected in higher synchronous activation along the ascending auditory pathway in the aging brain.

After the last session of auditory testing, inner ears were harvested and used for molecular and histological analysis. Ntf3 mRNA levels were significantly higher in the 95-week-old Ntf3stop:Slc1a3/CreERT mice than in their 95-week-old littermates carrying only the Ntf3stop transgene (Figure 4), indicating that we had achieved persistent transgenic expression. Furthermore, consistent with our prior studies (Sugawara et al., 2007), Ntf3 levels in control mice at 95 weeks were ~40% lower than those in 10-week-old controls. Notably, Ntf3 levels in

FIGURE 1 Ntf3 overexpression at mid-life slows the age-related decline in ABR peak 1 amplitude but does not alter age-related ABR and DPOAE threshold shifts. (a) Timeline of the experimental design. Ntf3 overexpressing (Ntf3stop:Slc1a3/CreERT) and control (Ntf3stop) mice were used in this study. Ntf3 overexpression was induced by intraperitoneal tamoxifen injection at 60 weeks of age (highlighted in blue). Baseline ABRs and DPOAEs were recorded 1 week before tamoxifen treatment (59 weeks of age) and at four later time points (61, 62, 64, and 95 weeks of age). After the last ABR and DPOAE tests, cochleae were collected and processed for either immunohistochemistry followed by confocal microscopy to evaluate HCs and IHC synapse counts or for RT-qPCR to evaluate Ntf3 mRNA expression. (b) Ntf3 overexpression starting at 60 weeks of age does not alter DPOAE thresholds during the following 35 weeks. (c) Ntf3 overexpression starting at 60 weeks of age does not alter ABR thresholds during the following 35 weeks. (d) Ntf3 overexpression starting at 60 weeks of age increases ABR peak 1 amplitudes 1 week later and slows the decline of ABR peak 1 amplitudes at 80 dB SPL during the following 34 weeks. Ntf3stop n = 7–13 mice; Ntf3Stop:Slc1a3/CreERT n = 7–17 mice. Two-way ANOVA followed by Sidak’s multiple comparisons test was used to evaluate statistical differences between Ntf3Stop and Ntf3Stop:Slc1a3/CreERT mice at each individual time point for either DPOAE threshold, ABR threshold or ABR peak1 amplitude. ** p < 0.01; *** p < 0.001. Error bars represent SEM.
Ntf3 Stop :Slc1a3/CreER T mice at 95 weeks were not statistically different from those seen in young control (Ntf3 Stop) mice, indicating that tamoxifen induction was sufficient to maintain Ntf3 expression in the old Ntf3 Stop :Slc1a3/CreER T mice at the same level as they had in their youth.

Consistent with the preservation of ABR peak 1 amplitudes in 95-week-old Ntf3 Stop :Slc1a3/CreER T mice, their IHC-SGN synapse counts were also similar to those found in 10-week-old Ntf3 Stop mice, and significantly higher than in the 95-week-old Ntf3 Stop littermates (Figure 5a,5b), demonstrating that Ntf3 overexpression prevented age-related IHC synaptopathy. Furthermore, we found a significant correlation among Ntf3 mRNA levels, synapse counts and ABR peak 1 amplitudes at 95 weeks of age (Figure 5c: ABR peak 1 amplitudes vs. Ntf3 expression level $r = 0.846 \ p < 0.0001$; IHC synapses vs. Ntf3 expression level $r = 0.733 \ p = 0.031$ and IHC synapses vs. ABR peak 1 amplitudes $r = 0.783 \ p = 0.017$).

In contrast, in agreement with the DPOAE thresholds shifts seen in both genotypes at 95 weeks (Figure 1b), Ntf3 Stop :Slc1a3/CreER T and Ntf3 Stop mice had similar levels of OHC loss at that age (Figure 6c). This indicates that supporting cell Ntf3 overexpression protects IHC-SGN synapses but not OHCs, which do not express the receptor for Ntf3 (TrkC) and only transiently express the receptor for Bdnf (TrkB) during the neonatal period (Knipper et al., 1996; Ylikoski et al., 1993).

3 | DISCUSSION

ARHL has reached epidemic proportions (Agrawal et al., 2008; Bainbridge & Wallhagen, 2014), and hearing impairment has been shown to contribute to cognitive decline and dementia (Livingston et al., 2020; Powell et al., 2021). Thus, developing therapies to
prevent ARHL is an important public health priority. Our results provide the first demonstration that increasing Ntf3 levels in the middle-aged cochlea promotes the maintenance of IHC-SGN synapses and their function during murine aging, supporting the potential of Ntf3 supplementation as a potential strategy to reduce the burden of ARHL in humans. However, the increased Ntf3 expression and IHC synapse preservation does not prevent OHC loss and the consequent age-related cochlear threshold shifts. These findings indicate that OHC survival during aging does not depend on Ntf3, SGNs, or IHC-SGN synapses, and that strategies to enhance OHC survival will be necessary to complement the potential therapeutic effects of Ntf3. Importantly, despite the threshold shifts observed in the aged Ntf3-overexpressing mice, amplitudes of most peaks of the ABR waveform were larger than in their age-matched controls, suggesting that the Ntf3-induced preservation of IHC-SGN synapses and ABR peak 1 amplitudes improves signaling along the ascending auditory pathway during aging.

Whereas good cochlear thresholds are key to maintaining the audibility of sounds, healthy neural populations are key to maintaining the intelligibility of sounds, especially in difficult listening situations, where the central nervous system likely pools responses from large population of auditory neurons to improve the signal-to-noise ratio (Lopez-Poveda, 2014). Histopathological studies of human autopsy specimens have demonstrated a dramatic loss of auditory nerve fibers in “normal-aging” adults, despite the survival of most of their IHC targets (Wu et al., 2019). It is likely that this IHC-SGN synapse loss and primary neural degeneration are key contributors to the classic complaint of those with ARHL, that is, problems understanding speech in a noisy environment (Lopez-Poveda, 2014). The present results suggest that Ntf3 therapies
FIGURE 4  Cochlear Ntf3 mRNA levels decrease by 40% between 10- and 95-week-old control mice, but expression levels in 95-week-old Ntf3stop:Slc1a3/CreERT mice remain the same as in young mice when tamoxifen is injected at 60 weeks of age. Ntf3 mRNA levels in cochleae from control (Ntf3stop) mice at 10 and 95 weeks of age (grey bars) and in 95-week-old Ntf3stop:Slc1a3/CreERT mice that were treated with tamoxifen at 60 weeks. 10-week-old Ntf3stop:Slc1a3/CreERT n = 9 cochleae; 95-week-old Ntf3stop:Slc1a3/CreERT n = 11 cochleae (only one cochlea per mouse was analyzed). Kruskal–Wallis test, followed by Dunn’s multiple comparisons test was used to evaluate differences among the three groups. * p < 0.05; ** p < 0.01. Error bars represent SEM.

could prevent or slow much of this age-related degradation in hearing abilities.

We previously showed that IHC-SGN synapse density and ABR peak 1 amplitude strongly correlate in young mice (Wan et al., 2014). Here, we demonstrate that these variables also correlate with Ntf3 expression levels in aged mice. Our results also show that activating Ntf3 overexpression in the middle-aged cochlea rapidly increases the amplitude of cochlear sound-evoked potentials without altering ABR or DPOAE thresholds. Remarkably, this does not occur when Ntf3 is overexpressed in young adults (2-month-old). This difference likely reflects the age-related decline in endogenous Ntf3 expression (Figure 4 and (Sugawara et al., 2007), that is, Ntf3 overexpression enhances IHC-SGN synapse numbers and/or function acutely only after endogenous Ntf3 expression is reduced due to aging. Together with the finding that Ntf3 overexpression in middle age prevents subsequent loss of IHC-SGN synapses, our results suggest that the age-related decline in endogenous Ntf3 expression contributes to age-related IHC synaptopathy and reductions in ABR peak 1 amplitudes.

Our previous studies on noise-induced synaptopathy showed that increasing cochlear Ntf3 levels promotes synapse preservation or regeneration when the neurotrophin is provided via transgenically driven overexpression (Wan et al., 2014), by direct Ntf3 application to the round window (Suzuki et al., 2016) or by AAV-mediated gene transfer (Hashimoto et al., 2019). Thus, we anticipate that both protein delivery and gene therapy, in combination with new approaches for Ntf3 delivery to the round window (Gunewardene et al., 2022; Wang et al., 2021) could also work for ARHL. Of course, a virus-mediated gene therapy approach would have the advantage of long-lasting expression that is likely necessary to preserve IHC-SGN synapses over years, similar to the effects we observed here in transgenic mice. However, other studies indicate that careful control of virus titer and levels of Ntf3 overexpression will be necessary to avoid negative side effects. For example, we found that while relatively modest levels of Ntf3 overexpression (2–4-fold over control) via AAV-mediated gene therapy (Hashimoto et al., 2019) or transgenesis (Wan et al., 2014) promote recovery of IHC-SGN synapses after noise exposure in young mice, higher Ntf3 overexpression levels in IHCs (50–100-fold over control) can increase IHC death after noise exposure (Hashimoto et al., 2019).

Synaptopathy is not only involved in the pathogenesis of ARHL but has been proposed to play early and critical roles in a number of neurological and neurodegenerative disorders (Henstridge et al., 2016). Thus, our findings in the cochlea raise the possibility that increasing the availability of factors that regulate synaptogenesis in the central nervous system during development might serve as therapies for degenerative disorders by slowing or preventing age-related synaptopathy.

4 | EXPERIMENTAL PROCEDURES

4.1 | Animals and tamoxifen treatment

To overexpress Ntf3 from adult supporting cells, we crossed Slc1a3/CreERT mice (Slc1a3 CreERT; JAX stock no. 012586) with Ntf3stop mice. The conditional Ntf3 overexpression transgene is under regulation of a strong ubiquitous promoter (CAGGS), which contains the cytomegalovirus (CMV) early enhancer element; the promoter, first exon and first intron of the chicken beta-actin gene; and the splice acceptor of the rabbit beta-globin gene. Between the CAGGS and the Ntf3 sequences, we included a floxed STOP cassette that prevents transgene expression until it is removed by the Cre recombinase (regular or tamoxifen inducible). Unless epigenetic mechanisms silence the transgene (which can occur), transgenic expression tends to be long-lasting.

Slc1a3/CreERT mice (Wang et al., 2012) were obtained from Jackson Laboratory while the engineering of the Ntf3stop mouse was described elsewhere (Wan et al., 2014). Ntf3stop:Slc1a3/CreERT mice and their controls were on a mixed background of C57BL/6 and FVB/N, and were genotyped to ensure that they do not carry the olf cadherin 23 allele associated with early onset progressive hearing loss present in C57BL/6 mice (Noben-Trauth et al., 2003). Cre-negative littermates (Ntf3stop) were used as control group. For the study, either 8-week-old or 60-week-old mice were gavaged with tamoxifen (200mg/kg/day) for 3 days. Mouse ages were chosen following criteria correlating maturational rates of mice and humans (Flurey et al., 2007; Hagan, 2017; The-Harrison-lab, n.d.). Since the two are not linearly correlated, these authors consider 3–6 month-old mice...
as mature adults, 10–15 month-old mice as middle-aged, and 18–24 month-old as old. Therefore, we used 8-week-old mice as young, 60-week-old as middle-aged, and 95-week-old as old mice. All animal procedures were approved by Institutional Animal Care and Use Committee of the University of Michigan, and all experiments were performed in accordance with relevant guidelines and regulations.

### 4.2 Physiological analyses

Inner ear physiology, including auditory brainstem responses (ABRs, the summed activity of auditory afferent pathways to short tone bursts), and distortion product otoacoustic emissions (DPOAEs), was performed on mice anesthetized with a mixture of ketamine
CASSINOTTI et al. (100 mg/kg, i.p.) and xylazine (20 mg/kg, i.p.). For the middle-aged mice, the first recording was performed at 59 weeks of age (baseline), followed by tamoxifen treatment at 60 weeks of age and additional measurements at 61, 62, 64, and 95 weeks of age. For the young adult mice, the first recording was performed at 7 weeks of age (baseline), followed by tamoxifen treatment at 8 weeks of age and additional measurement at 9 weeks of age. For ABR recordings, acoustic stimuli were delivered through a closed acoustic system, consisting of two sound sources (CDMG15008-03A, CUI) and an electret condenser microphone (FG-23329-PO7, Knowles) as an in-dwelling probe microphone. Three needle electrodes were placed into the skin at the dorsal midline: one close to the neural crest, one behind the left pinna, and one at the base of the tail (ground). ABR potentials were evoked with 5 ms tone pips (0.5 ms rise-fall, with a $\cos^2$ envelope, at 40/s) delivered to the eardrum at log-spaced frequencies from 5.6 to 42.25 kHz. The response was amplified (10,000X) and filtered (0.3-3 kHz) with an analog-to-digital board in a PC-based data-acquisition system. Sound pressure level was raised in 5 dB steps from 20 to 80 dB SPL. At each level, 1024 responses were averaged (with stimulus polarity alternated) after “artifact rejection” above 15 $\mu$V. The DPOAEs, in response to two primary tones of frequencies $f_1$ and $f_2$, were recorded at $(2 \times f_1) - f_2$, with $f_2/f_1 = 1.2$, and the $f_2$ level 10 dB lower than the $f_1$ level. Stimuli were raised in 5 dB steps from 20 to 80 dB. The ear-canal sound pressure was amplified and digitally sampled at 4 $\mu$s intervals. DPOAE thresholds were defined as the lower SPL where $(2f_1 - f_2) - (2f_1 - f_2\text{Nse}) > 0$. These acoustic signals, generated by outer hair cells and measurable in the ear canal, are useful for differential diagnosis: attenuation of ABRs without a change in DPOAEs provides strong evidence for IHC-SGN synaptic or neural dysfunction (Kujawa & Liberman, 2009). Both ABR and DPOAE recordings were performed using the EPL Cochlear Function Test Suite (Mass Eye and Ear, Boston). ABR thresholds, ABR peak 1 amplitudes and latencies, ABR waveforms and DPOAE thresholds were analyzed with ABR peak Analysis software (Mass Eye and Ear, Boston) and Microsoft Excel.

FIGURE 6 Ntf3 overexpression starting at mid-life does not alter age-related OHC loss. (a) Representative confocal images of the 16 kHz region of Ntf3stop and Ntf3stop:Slc1a3/Creat groups showing mild OHC loss without IHC loss in both groups at 95 weeks of age. (b) Quantitative analysis shows no IHC loss. (c) Both groups show equal degrees of mild OHC loss. Ntf3stop n = 3–6 cochleae; Ntf3stop:Slc1a3/Creat n = 5–6 cochleae. Only one cochlea from each mouse was analyzed. 2-tailed t-test was used to evaluate differences between Ntf3stop and Ntf3stop:Slc1a3/Creat groups at an individual cochlear region (frequency, kHz). Non-significant differences between groups were found when evaluating either ICH or OHC survival. Error bars represent SEM.

4.3 | RNA isolation and quantitative RT-PCR

Mice (10- and 95-weeks-old) were euthanized by cervical dislocation followed by decapitation and the inner ear temporal bones were harvested. Total RNA was purified from whole individual inner ears using RNA extraction kit and Qiazol Reagent (RNeasy mini kit; Qiagen). DNase treatment was performed immediately after total RNA purification (RNase-free; Qiagen). First strand cDNA was prepared from 400ng of total RNA and the complementary DNA strand was
4.4 Immunostaining for hair cells and synaptic counts

Inner ear tissues from 10- and 95-week-old mice were dissected and fixed in 4% paraformaldehyde in 0.01 M phosphate-buffered saline (PBS) for 2 h at room temperature, followed by decalcification in 5% EDTA at 4°C for 5 days. Cochlear tissues were microdissected and permeabilized by freeze–thawing in 30% sucrose. The microdissected tissues were incubated in blocking buffer containing 5% normal goat serum and 0.3% Triton X-100 in PBS for 1 h. Tissues were then incubated in primary antibodies (diluted in 1% normal goat serum and 0.3% Triton X-100 in PBS) at 37°C overnight. The primary antibodies used in this study were as follows: anti-Ctbp2 (BD Biosciences, San Jose, CA; 1:200; catalog no. 612044), anti-GluR2 (Millipore, Billerica, MA; 1:1000; catalog no. MAB397), and anti-MyoVIIa (Proteus Biosciences, Ramona, CA; 1:100; catalog no. 25–6790). Tissues were then incubated with appropriate Alexa Fluor-conjugated fluorescent secondary antibodies (Invitrogen, Carlsbad, CA; 1:1000 diluted in 1% normal goat serum and 0.3% Triton X-100 in PBS; AF488 IgG2a catalog no. A-21131; AF568 IgG1 catalog no. A-21124; AF647 IgG catalog no. A-21244) for 1 h at room temperature. The tissues were mounted on microscope slides in ProLong Diamond Antifade Mountant (Thermo Fisher Scientific). All pieces of each cochlea were imaged at low power (10X magnification) to convert cochlear location into frequency (tonotopic mapping) using a custom plug-in to ImageJ (1.53c NIH, MD) available at the website of the Eaton–Peabody Laboratories (EPL). Cochlear tissues from 8 to 32 kHz regions were used for further analyses. Confocal z-stacks of cochlear tissues were taken using a Leica SP8 confocal microscope. Images for hair cell counts were taken under 40X magnification. For inner hair cell synapse counts, z-stacks (0.3 μm step size) were taken under 63X (+2.4X optical zoom) magnification spanning the entire IHC height to ensure all synapses were imaged. Imaging and analyses of cochlear hair cells and synapses were performed as previously described in (Wan et al., 2014). Briefly, image/J Fiji software (version 1.53c, NIH, MD) was used for image processing and quantification. One cochlea from each of five or six animals was imaged for each experiment, with 3 images acquired at each cochlear region. For hair cell quantification, the number of inner and outer hair cells at specific cochlear regions in each animal was determined based on the MyoVIIa channel and counted manually using ImageJ/Fiji software multi-point counter tool. For synapse counts, CtBP2 and GluR2 puncta in each image stacks were also captured and counted manually using ImageJ/Fiji software multi-point counter tool. Synaptic counts of each z-stack were divided by the number of IHCs, which could be visualized by staining of MyoVIIa antibody. Each individual image usually contained 8–10 IHCs. For figures, one representative image was selected from amongst the 15–18 images from the specified frequency channel.

4.5 Statistical analysis and correlations

Graphics and statistical tests were performed using GraphPad Prism version 9.3.1 for Windows (GraphPad Software, www.graphpad.com). Data sets with normal distributions were analyzed with parametric tests whereas non-parametric tests were used for sets that did not conform to normality criteria. We used 2-way ANOVA, followed by Sidak’s multiple comparisons test to compare DPOAE thresholds, ABR thresholds, and ABR peak1 amplitudes at each time point (59, 60, 62, 64 and 95 weeks) between Ntf3stop:Slc1a3/CreER T and Ntf3stop (Figures 1b,c). Two-way ANOVA followed by Sidak’s multiple comparisons test was also used to evaluate ABR peak 1 amplitudes between groups over time at an individual cochlear region (frequency, kHz) (Figure 2a). Two-way ANOVA followed by Sidak’s multiple comparisons test was used to evaluate the acute effect of Ntf3 overexpression on DPOAE thresholds, ABR thresholds, and ABR peak1 amplitudes (Figure 3) within each genotype. Ntf3 mRNA expression levels were analyzed using Kruskal–Wallis test followed by Dunn’s multiple comparisons test. Quantification of confocal microscopy images were analyzed by two-tailed t-test for inner and outer hair cells survival, and 1-way ANOVA followed by Tukey’s multiple comparisons test for IHC-SGNs synapse density. Correlations were evaluated using Spearman correlation test. All p < 0.05 were considered as statistically significant.
AUTHOR CONTRIBUTIONS
LRC and GC designed the research studies. LRC, LJ, BCB, and NDC conducted experiments. LRC, LJ, BCB, NDC, ASD, and DCK acquired data. LRC, BCB, ASD, and GC analyzed data. LRC, LJ, BCB, NDC, ASD, DCK, MCL, and GC wrote the manuscript.

ACKNOWLEDGMENTS
This work was supported by NIH R01DC004820 (GC), R01DC018500 (GC), T32DC005356 Advanced Research Training in Otolaryngology (NDC), R01 DC0188 (MCL). We thank Michael Hayes for helping with mouse colony management.

CONFLICT OF INTEREST
GC and MCL are scientific founders of Decibel Therapeutics, have equity interest in the company and have received compensation for consulting. The company was not involved in this study.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Luis R. Cassinotti https://orcid.org/0000-0002-9815-6826
Beatriz C. Borges https://orcid.org/0000-0001-7525-3924
Nathan D. Cass https://orcid.org/0000-0003-2654-2812
David C. Kohrman https://orcid.org/0000-0001-6888-6889
M. Charles Liberman https://orcid.org/0000-0002-1973-1730
Gabriel Corfas https://orcid.org/0000-0001-5412-9473

REFERENCES
Agrawal, Y., Platz, E. A., & Niparko, J. K. (2008). Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Archives of Internal Medicine, 168(14), 1522-1530. https://doi.org/10.1001/archinte.168.14.1522
Bainbridge, K. E., & Wallhagen, M. I. (2014). Hearing loss in an aging American population: extent, impact, and management. Annual Review of Public Health, 35, 139-152. https://doi.org/10.1146/annurev-publhealth-032013-182510
Ernfors, P., Van De Water, T., Loring, J., & Jaenisch, R. (1995). Complementary roles of BDNF and NT-3 in vestibular and auditory development. Neuron, 14(6), 1153-1164. https://doi.org/10.1016/0896-6273(95)90263-5
Farinas, I., Jones, K. R., Backus, C., Wang, X. Y., & Reichardt, L. F. (1994). Severe sensory and sympathetic deficits in mice lacking neurotrophin-3. Nature, 369(6482), 658–661. https://doi.org/10.1038/369658a0
Flurey, K. K., Currer, J. M., & Harrison, D. E. (2007). The Mouse in Aging Research. In S. B. J. Fox, M. Davison, C. Newcomer, F. Quimby, & A. Smith (Eds.), The Mouse in Biomedical Research (2nd ed., pp. 637–672). Elsevier.
Gunewarde, N., Lam, M., Ma, Y., Caruso, F., Wagstaff, S., Richardson, R. T., & Wise, A. K. (2022). Pharmacokinetics and biodistribution of supraparticle-delivered neurotrophin 3 in the Guinea pig cochlea. Journal of Controlled Release, 342, 295–307. https://doi.org/10.1016/j.jconrel.2021.12.037
Hagan, C. (2017). When are mice considered old? Retrieved from https://www.jax.org/news-and-insights/jax-blog/2017/november/when-are-mice-considered-old
Hashimoto, K., Hickman, T. T., Suzuki, J., Li, L., Koomran, D. C., Corfas, G., & Liberman, M. C. (2019). Protection from noise-induced cochlear synaptopathy by virally mediated overexpression of NT3. Scientific Reports, 9(1), 15362. https://doi.org/10.1038/s41598-019-51724-6
Henstridge, C. M., Pickett, E., & Spires-Jones, T. L. (2016). Synaptic pathology: A shared mechanism in neurological disease. Aging Research Reviews, 28, 72–84. https://doi.org/10.1016/j.arr.2016.04.005
Huddle, M. G., Goman, A. M., Kernizan, F. C., Foley, D. M., Price, C., Frick, K. D., & Lin, F. R. (2017). The Economic Impact of adult hearing loss: A systematic review. JAMA Otolaryngology. Head & Neck Surgery, 143(10), 1040–1048. https://doi.org/10.1001/jamaoto.2017.12143
Knipper, M., Zimmermann, U., Rohbock, K., Kopschall, I., & Zemper, H. P. (1996). Expression of neurotrophin receptor trkB in rat cochlear hair cells at time of rearrangement of innervation. Cell and Tissue Research, 283(3), 339–353. https://doi.org/10.1007/s004410050545
Kohrman, D. C., Borges, B. C., Cassinotti, L. R., Li, L., & Corfas, G. (2021). Axon-glia interactions in the ascending auditory system. Developmental Neurobiology, 81(5), 546–567. https://doi.org/10.1002/dneu.22813
Kujawa, S. G., & Liberman, M. C. (2006). Acceleration of age-related hearing loss by early noise exposure: Evidence of a misspent youth. The Journal of Neuroscience, 26(7), 2115–2123. https://doi.org/10.1523/JNEUROSCI.4985-05.2006
Kujawa, S. G., & Liberman, M. C. (2009). Adding insult to injury: Cochlear nerve degeneration after “temporary” noise-induced hearing loss. The Journal of Neuroscience, 29(45), 14077–14085. https://doi.org/10.1523/JNEUROSCI.2845-09.2009
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gittlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Oggunniyi, A., & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet commission. Lancet, 396(10248), 413–446. https://doi.org/10.1016/S0140-6736(20)30367-6
Lopez-Poveda, E. A. (2014). Why do I hear but not understand? Stochastic undersampling as a model of degraded neural encoding of speech. Frontiers in Neuroscience, 8, 348. https://doi.org/10.3389/fnins.2014.00348
Makary, C. A., Shin, J., Kujawa, S. G., Liberman, M. C., & Merchant, S. N. (2011). Age-related primary cochlear neuronal degeneration in human temporal bones. Journal of the Association for Research in Otologyngology, 12(6), 711–717. https://doi.org/10.1007/s10168-011-0283-2
Noben-Trauth, K., Zheng, Q. Y., & Johnson, K. R. (2003). Association of cadherin 23 with polygenic inheritance and genetic modification of sensorineural hearing loss. Nature Genetics, 35(1), 21–23. https://doi.org/10.1038/ng1226
Powell, D. S., Oh, E. E., Lin, F. R., & Deal, J. A. (2021). Hearing impairment and cognition in an aging world. Journal of the Association for Research in Otologyngology, 22(4), 387–403. https://doi.org/10.1016/j.jaro.2021-07-00799-y
Sergeyenko, Y., Lall, K., Liberman, M. C., & Kujawa, S. G. (2013). Age-related cochlear synaptopathy: An early-onset contributor to auditory functional decline. The Journal of Neuroscience, 33(34), 13668–13694. https://doi.org/10.1523/JNEUROSCI.1783-13.2013
Stankovic, K. M., & Corfas, G. (2003). Real-time quantitative RT-PCR for low-abundance transcripts in the inner ear: Analysis of neurotrophic factor expression. Hearing Research, 185(1–2), 97–108. https://doi.org/10.1016/S0378-5955(03)00298-3
Sugawara, M., Murtie, J. C., Stankovic, K. M., Liberman, M. C., & Corfas, G. (2007). Dynamic patterns of neurotrophin 3 expression in the postnatal mouse inner ear. The Journal of Comparative Neurology, 501(1), 30–37. https://doi.org/10.1002/cne.21227
Suzuki, J., Corfas, G., & Liberman, M. C. (2016). Round-window delivery of neurotrophin 3 regenerates cochlear synapses after acoustic
overexposure. *Scientific Reports*, 6, 24907. https://doi.org/10.1038/srep24907

The-Harrison-lab. Life span as a biomarker. Retrieved from https://www.jax.org/research-and-faculty/research-labs/the-harrison-lab/gerontology/life-span-as-a-biomarker

Viana, L. M., O’Malley, J. T., Burgess, B. J., Jones, D. D., Oliveira, C. A., Santos, F., Merchant, S. N., Liberman, L. D., & Merchant, S. N. (2015). Cochlear neuropathy in human presbycusis: Confocal analysis of hidden hearing loss in post-mortem tissue. *Hearing Research*, 327, 78–88. https://doi.org/10.1016/j.heares.2015.04.014

Wan, G., Gomez-Casati, M. E., Gigliello, A. R., Liberman, M. C., & Corfas, G. (2014). Neurotrophin-3 regulates ribbon synapse density in the cochlea and induces synapse regeneration after acoustic trauma. *eLife*, 3, 1–18. https://doi.org/10.7554/eLife.03564

Wang, J., Youngblood, R., Cassinotti, L., Skoumal, M., Corfas, G., & Shea, L. (2021). An injectable PEG hydrogel controlling neurotrophin-3 release by affinity peptides. *Journal of Controlled Release*, 330, 575–586. https://doi.org/10.1016/j.jconrel.2020.12.045

Wang, Y., Rattner, A., Zhou, Y., Williams, J., Smallwood, P. M., & Nathans, J. (2012). Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity. *Cell*, 151(6), 1332–1344. https://doi.org/10.1016/j.cell.2012.10.042

Wu, P. Z., Liberman, L. D., Bennett, K., de Gruttola, V., O’Malley, J. T., & Liberman, M. C. (2019). Primary Neural Degeneration in the

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Cassinotti, L. R., Ji, L., Borges, B. C., Cass, N. D., Desai, A. S., Kohrman, D. C., Liberman, M. C., & Corfas, G. (2022). Cochlear Neurotrophin-3 overexpression at mid-life prevents age-related inner hair cell synaptopathy and slows age-related hearing loss. *Aging Cell*, 21, e13708. https://doi.org/10.1111/ace1.13708

Human Cochlea: Evidence for Hidden Hearing Loss in the Aging Ear. *Neuroscience*, 407, 8–20. https://doi.org/10.1016/j.neuroscience.2018.07.053

Ylikoski, J., Pirvola, U., Moshnyakov, M., Palgi, J., Arumae, U., & Saarma, M. (1993). Expression patterns of neurotrophin and their receptor mRNAs in the rat inner ear. *Hearing Research*, 65(1–2), 69–78. https://doi.org/10.1016/0378-5955(93)90202-c